SEOUL, South Korea, April 8, 2021 /PRNewswire/ — A analysis paper by a South Korean bio tech firm that demonstrated the drug repurposing of Niclosamide, an anthelmintic identified to have wonderful therapeutic efficacy in opposition to novel coronavirus an infection (COVID-19), was printed in the world-renowned SCI (Science and Technology Journal Citation Index)-level worldwide journal and is attracting worldwide consideration.

Hyundai Bioscience (Symbol 048410), a KOSDAQ listed firm, introduced on April 8 that CNPharm, its main shareholding bio tech firm, printed a analysis paper that proves the profitable repurposing (or repositioning) of Niclosamide for COVID-19 remedy by utilizing a drug supply system (DDS), an unique expertise of CNPharm. The paper was not too long ago listed in Polymers, a world-renowned scientific journal in the subject of polymer science. CNPharm additionally filed worldwide patent functions on this DDS expertise for repurposing Niclosamide as COVID-19 remedy.

Although Niclosamide has been discovered to be efficient for varied illnesses up to now, that is the first time {that a} paper demonstrating drug repurposing by way of varied examine outcomes has been printed in an SCI-level worldwide journal. This signifies that the worldwide pharmaceutical neighborhood has acknowledged that CNPharm, the dad or mum firm of Hyundai Bioscience, is main the approach to repurpose the anthelmintic drug. As a end result, worldwide curiosity in CP-COV03, an oral drug to fight COVID-19 developed by CNPharm, is anticipated to extend.

In the paper titled ‘Niclosamide–Clay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability towards COVID-19 Treatment’, an experimental end result was additionally revealed that the bioavailability of the repurposed Niclosamide formulation utilizing CNPharm’s cationic drug supply system (DDS) was elevated by 60% in comparison with Yomesan, the present anthelmintic formulation of Niclosamide.

An official at Hyundai Bioscience said that this is the first time that Niclosamide’s bioavailability enchancment for drug repurposing has been printed in a global journal. In addition to COVID-19, we plan to broaden the scope of repurposing in order that it may be utilized to numerous intractable illnesses equivalent to metastatic most cancers and resistant most cancers. In explicit, it was reported that COVID-19 variants, which have not too long ago raised considerations of the worldwide neighborhood, might be suppressed by repurposed Niclosamide utilizing CNPharm’s drug supply system. A follow-up examine is in progress.

Niclosamide, which Bayer launched in 1958, was chosen as the No. 1 candidate for the remedy of COVID-19 amongst 48 main medicine in the world in April, 2020 by Institut Pasteur Korea. It is named a candidate drug that may deal with intractable illnesses equivalent to resistant most cancers and metastatic most cancers, in addition to varied viral illnesses. However, because of its nature of anthelmintic drug, two difficulties exist equivalent to a low absorption fee in the physique and a particularly quick half-life of the drug focus in the blood.  These have acted as obstacles to repurposing of Niclosamide for many years.

Based on CNPharm’s unique expertise, Hyundai Bioscience has dramatically improved the absorption fee and half-life of Niclosamide final 12 months, creating CP-COV03, an oral remedy for COVID-19.  This goals to turn into the world’s first oral drug for the remedy of the virus which is at present in preparations for medical trials. CP-COV03 was confirmed from a current animal testing to take care of totally efficient drug focus (IC100) in the blood, or 100% antiviral inhibitory focus stage, for greater than 12 hours by single dose, and it’s anticipated as a really possible candidate of the sport changer to finish the coronavirus pandemic.

About Hyundai Bioscience

HYUNDAI BIOSCIENCE is a biotechnology firm that develops and commercializes bio-fusion expertise with the objective of delivering lively components safely and effectively to focused areas of the physique. Hyundai Bioscience’s Organic-Inorganic Hybrid Technology is a novel drug supply system expertise that enables the selective and efficient supply of lively substances on the goal space in mixture with bio-friendly supply automobiles. Applying its expertise in the fields of tumor-targeted medicine and even pores and skin & scalp care, Hyundai Bioscience will proceed to broaden its enterprise scope by introducing revolutionary biotechnology and new efficient merchandise.

SOURCE Hyundai Bioscience

Related Links

http://www.hyundaibioscience.com/



Sources

Leave a Reply

Your email address will not be published. Required fields are marked *